Revium Recovery Ltd. (Revium Rx)

reviumrx.com

High-Tech Company
Public Company

(OTC Pink: RVRC)

TECH VERTICALS

Antibiotics, Biologicals, Biotechnology, Drug Delivery, Life Sciences, MedTech, Nanotechnology

General Data

Sector	Biomed
Company Stage:	R&D
Established	2020
Number of Employees	6
Reg. Number:	abCDe

DESCRIPTION

Revium Rx utilizes a novel drug delivery technology to develop encapsulated therapeutics for several therapeutic indications, including antibiotics for antimicrobial-resistant bacteria, a lipid-based adjuvant for solid carcinogenic tumors, and immunization. The company's technology integrates well-defined active substances with a proprietary, clinically proven drug-loading process to produce lipid-based particle carrier compositions that address unmet clinical needs in key fields such as infectious diseases, cancer, and immunology.

TECHNOLOGY

Revium's proprietary drug delivery platform for enhanced therapeutics integrates clinically proven nanoparticles, a proprietary drug loading and release technology, and specialized lipid-based microparticles carrier compositions.

Products and Phases

Product	Phase
Nano-Mupirocin	Pre-clinical, first candidate to enter CT Phase within 12 months.
Revium's liposomal nano-Mupirocin is a formulation of the approved, highly effective anti-bacterial drug Mupirocin, which is currently limited to topical use. The novel proprietary formulation of nano-Mupirocin will be administered systemically, providing long circulation time and enhanced delivery of Mupirocin to inflammation sites. In several preclinical studies carried out by the NIH STI group, nano-Mupirocin has demonstrated low minimum inhibitory concentration (MIC) levels as well as excellent efficacy in preclinical models against multiple resistant bacterial strains, including MRSA and VRE.
Nano-Candesartan	Preclinical Studies
Revium Rx develops nanoparticle-encapsulated candesartan (ARB or AT-1 receptor inhibitor) as a targeted and potent adjuvant to solid tumors treatment to allow better treatment outcomes. The novel adjuvant developed by Revium Rx aims to overcome the limitation of systemic ARB administration and significantly improve treatment success rates by enabling enhanced permeability and retention (EPR effect) without affecting systemic blood pressure. Preclinical studies carried out at the Hebrew University of Jerusalem have shown that ARB targeting can effectively modulate the immune response within tumors, increasing the effectiveness of current therapies.
LPLT Vaccine development	Preclinical Studies
Comprised of a unique assembly of novel lipids with biological components, Revium Rx's lipid-based Protein-Loaded Technology (LPLT) microparticles have demonstrated promising efficacy in preclinical models of infectious diseases. The unique lipids utilized in the formulation modify the immune response in animal models specifically and effectively, potentially holding significant clinical opportunities for COVID-19, West Nile, and Zika viruses.

	TARGET MARKETS
	Pharmaceutical Companies, HMOs, Governments, Oncology Centers.

	BUSINESS MODEL
	B2B

CONTACT INFO

Expand / Collapse All

Main Address: Herzliya, Israel

Address	10 Hamenofim St.
City	Herzliya
Country	Israel
Zip	4672561

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. David Akunis	CEO	Flometrica (CEO)
Ms. Inna Martin	COO	LIVEKIDNEY.BIO (Chief Business Officer)
Dr. Erez Koren	CTO	Lipovation (CTO)
Mr. Arie Gordashnikov	CFO
Mr. Yoram Drucker	VP, Business Development	IR-MED (VP, Business Development & Chairman)
Mr. Amir Avraham	Internal Audit	OCON Therapeutics (CFO)
Prof. Yechezkel Barenholz	Founder & Inventor	Capital Nano (Advisory Board Member)

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Founder, Aimmune Therapeutics (acquired by Nestle)
abC Defghij	Board Member	COO, Revium RX
abC Defghij	Board Member	CFO, BEESENSE
abC Defghij	Board Member	Regional Director, Euro Exim Bank

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Reverse Merger

Dec. 09, 2020

R&D

abCDe

	Acquisitions made by Revium Rx

Acquired Company	Sector	Date	Amount	Remarks
abC Defghij	Biomed...	Feb. 04, 2025	abCDe

Last Updated:	abCDe
IVC Number:	abCDe